Keytruda and Inlyta Combo Approved in Europe for Untreated Advanced Kidney Cancer
News
The European Commission has approved a combination of Keytruda (pembrolizumab) with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on ... Read more